Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonitoclax + Azacitidine in Relapsed/Refractory AML
NCT07303660Phase 1Recruiting
- Sponsor
- Lomond Therapeutics
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of lonitoclax in acute myeloid leukemia (AML) (8 arms), sponsored by Lomond Therapeutics. Primary endpoint: Recommended Phase 2 Dose. Started Nov 2025; status: recruiting.
02
Drugs
lonitoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07303660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07303660.